Positive vs. Negative TB Skin Test: What You Need to Know

The tuberculin skin test (TST), commonly known as the PPD test, is a widely used screening tool for latent tuberculosis infection (LTBI). Understanding the results of this test, whether positive or negative, is crucial for individuals and healthcare providers alike. This distinction guides further diagnostic steps, treatment decisions, and public health interventions.

A positive TST indicates that an individual’s immune system has, at some point, encountered the bacterium that causes tuberculosis, Mycobacterium tuberculosis. This encounter could have been due to active TB disease, latent TB infection, or even prior BCG vaccination. Therefore, a positive result doesn’t automatically mean someone has active, contagious TB.

Conversely, a negative TST suggests that the individual has likely not been infected with Mycobacterium tuberculosis. However, it’s important to note that a negative result doesn’t offer absolute certainty. False negatives can occur, especially in individuals with weakened immune systems or shortly after initial infection.

Understanding the Tuberculin Skin Test (TST)

The TST is a diagnostic procedure that involves injecting a small amount of purified protein derivative (PPD) tuberculin intradermally, typically on the forearm. The body’s immune response to this protein is then measured after 48 to 72 hours by assessing the size of any resulting bump or induration. This reaction is a key indicator of past exposure to the TB bacterium.

The principle behind the TST relies on cell-mediated immunity. If a person has been infected with Mycobacterium tuberculosis, their immune system will have developed T-lymphocytes that recognize TB antigens. When these specific lymphocytes encounter the PPD injected during the test, they trigger an inflammatory response at the injection site, leading to the characteristic induration.

This immunological memory is what the TST aims to detect. It’s a sensitive test, capable of identifying even past, non-symptomatic infections. However, its interpretation requires careful consideration of various factors that can influence the outcome.

How the TST is Administered

The administration of the TST is a standardized procedure performed by trained healthcare professionals. A small amount of PPD tuberculin, typically 0.1 mL, is injected just beneath the surface of the skin in the forearm. This technique is known as an intradermal injection.

The injection should create a small, pale bump, often referred to as a wheal, which usually disappears within a few minutes. Proper administration is critical to ensure accurate absorption of the PPD and to avoid subcutaneous injection, which would lead to an unreliable result. The site is then marked, and the individual is instructed to return for a reading.

The 48 to 72-hour timeframe is essential for allowing the immune response to develop and become measurable. Reading the test too early or too late can lead to misinterpretation of the results.

Reading and Interpreting the TST Result

The interpretation of a TST result hinges on the measurement of the induration, not redness, at the injection site. The healthcare provider will carefully feel the area for any raised, hardened tissue. If induration is present, its diameter is measured in millimeters across the forearm.

The significance of the induration size is not absolute and depends on the individual’s risk factors for TB exposure and infection. What might be considered a positive reaction in a low-risk individual could be considered negative or borderline in a high-risk person. This risk stratification is fundamental to accurate interpretation.

For example, an induration of 5 millimeters or more is considered significant in individuals with known close contact to an infectious TB case, those with HIV infection, or organ transplant recipients. A 10-millimeter induration is considered significant in immigrants from countries with high TB prevalence, injection drug users, and residents of high-risk congregate settings. For individuals with no known risk factors, an induration of 15 millimeters or more is generally considered positive.

What a Positive TB Skin Test Means

A positive TST signifies that the individual’s immune system has reacted to the PPD antigen, indicating exposure to Mycobacterium tuberculosis. This exposure could have occurred recently or many years ago.

It is crucial to understand that a positive TST does not equate to having active tuberculosis disease. Many individuals with a positive TST have latent TB infection (LTBI), meaning they are infected but the bacteria are inactive and not causing symptoms. These individuals cannot spread TB to others.

However, a positive test also necessitates further investigation to rule out active TB disease, especially if the individual has symptoms suggestive of the illness. This follow-up is vital for both the individual’s health and for preventing potential transmission.

Causes of a Positive TST

The primary cause of a positive TST is infection with Mycobacterium tuberculosis. This infection can be either latent or active.

Another significant factor is the Bacillus Calmette-Guérin (BCG) vaccine. While not widely used in the United States, the BCG vaccine is administered in many other countries to prevent severe forms of TB in children. This vaccine contains live, attenuated tubercle bacilli and can cause a positive TST reaction, even in the absence of natural TB infection. Distinguishing between a BCG-induced positive and a true TB infection positive can be challenging.

Finally, other non-tuberculous mycobacteria (NTM) can also cause a positive TST, though this is less common and typically requires a larger induration size to be considered significant. These are different species of bacteria that share some similarities with Mycobacterium tuberculosis.

Next Steps After a Positive TST

A positive TST is not a diagnosis of active TB disease but rather an indication of TB infection. The immediate next step is usually a medical evaluation to assess for symptoms of active TB and to determine if the infection is latent or active.

This evaluation typically includes a chest X-ray to look for signs of active disease in the lungs. Sputum samples may also be collected for microscopic examination and culture to detect the presence of live TB bacteria. These tests help differentiate between LTBI and active TB disease.

If active TB disease is diagnosed, treatment with a specific regimen of antibiotics is initiated to cure the infection and prevent its spread. If LTBI is diagnosed, preventive treatment with antibiotics may be recommended to reduce the risk of the infection progressing to active disease later in life.

Living with Latent TB Infection (LTBI)

Having LTBI means that TB bacteria are present in the body but are not causing symptoms. The immune system is keeping the bacteria under control, preventing them from multiplying and causing illness.

Individuals with LTBI are not contagious and cannot spread the bacteria to others. However, there is a risk that the latent infection could become active in the future, particularly if the immune system weakens due to factors like HIV, diabetes, or certain medications.

Preventive treatment for LTBI, typically involving a course of antibiotics, is highly effective in killing the dormant bacteria and significantly reducing the risk of developing active TB disease. This treatment is a crucial public health strategy for controlling TB.

What a Negative TB Skin Test Means

A negative TST result generally indicates that the individual has not been infected with Mycobacterium tuberculosis. This is the most common outcome for many people undergoing the test.

However, a negative result is not always definitive, and certain circumstances can lead to a false negative. It is essential to understand these limitations to avoid a false sense of security.

Therefore, a negative TST should be interpreted in conjunction with the individual’s clinical presentation and risk factors.

Reasons for a False Negative TST

Several factors can lead to a false negative TST result, meaning the test indicates no infection when one actually exists. One common reason is a weakened immune system, such as in individuals with HIV/AIDS, those undergoing chemotherapy, or people with certain chronic illnesses.

Another significant cause of false negatives is the timing of the test. If the test is performed too soon after exposure to TB bacteria, the immune system may not have had enough time to develop a detectable reaction. This is particularly relevant in recent exposures.

Additionally, certain factors related to the test administration or interpretation can contribute to false negatives. These include improper injection technique, incorrect measurement of the induration, or the use of expired PPD antigen. Elderly individuals and those with overwhelming TB disease may also have impaired immune responses that result in a negative test.

When a Negative TST Might Still Warrant Concern

Even with a negative TST, there are situations where continued concern for TB infection is warranted. This is especially true if the individual has symptoms suggestive of active TB disease, such as a persistent cough, fever, night sweats, or unexplained weight loss.

If a person has had a known recent exposure to someone with infectious TB and their initial TST is negative, repeat testing may be recommended after a period of 8 to 10 weeks, known as the “window period.” This allows for the immune response to develop if an infection occurred.

Furthermore, if an individual has a history of a previous positive TST that is now negative, it could indicate that their immune response has waned, or there might be issues with the current test. In such cases, further diagnostic workup might be necessary based on clinical judgment.

The Role of Interferon-Gamma Release Assays (IGRAs)

Interferon-gamma release assays (IGRAs) are blood tests that can also detect TB infection. They are often used as an alternative or adjunct to the TST, particularly in individuals who may have a false negative TST due to the BCG vaccine or an anergic (non-reactive) immune system.

IGRAs measure the amount of interferon-gamma released by a person’s white blood cells when exposed to TB-specific antigens in a laboratory setting. This method is less affected by prior BCG vaccination than the TST.

While IGRAs offer advantages, they also have limitations and do not replace the need for clinical evaluation and other diagnostic tests when TB is suspected. The choice between TST and IGRA often depends on individual circumstances, cost, and local laboratory capabilities.

Practical Scenarios and Interpretations

Understanding how TST results are interpreted in real-world scenarios can clarify their significance. Consider a healthcare worker who has regular contact with patients who may have TB. A positive TST in this individual, even without symptoms, would necessitate a chest X-ray and potentially other tests to rule out active disease and discuss LTBI preventive therapy.

Conversely, a traveler returning from a high-TB prevalence country who has a negative TST and no symptoms is generally considered to be at low risk for TB infection. However, if they develop a persistent cough or fever after returning, a re-evaluation, possibly including repeat testing, would be prudent.

A person with a history of BCG vaccination who develops a small induration on their TST might be considered to have a false positive due to the vaccine. However, if the induration is significant, or if they have other risk factors, further investigation using an IGRA or clinical assessment would be recommended.

Case Study 1: The Asymptomatic Individual with a Positive TST

Maria, a 35-year-old woman with no specific TB risk factors, undergoes a TST as part of a pre-employment screening. She returns 48 hours later, and a 12mm induration is noted on her forearm. She reports feeling completely healthy and has no cough, fever, or weight loss.

In Maria’s case, the 12mm induration is considered positive according to CDC guidelines for individuals without significant risk factors. The next step is a chest X-ray to rule out active TB disease. If the X-ray is normal, she will be diagnosed with latent TB infection (LTBI) and offered preventive therapy to reduce her lifetime risk of developing active TB.

This scenario highlights that a positive TST is a signal for further investigation, not an immediate diagnosis of illness. It’s an opportunity to proactively manage potential infection.

Case Study 2: The Individual with a Known Exposure and Negative TST

John’s roommate was recently diagnosed with active pulmonary TB. John is advised to get a TST. His initial test, performed two weeks after his roommate’s diagnosis, shows no induration, resulting in a negative reading.

Because of the recent close contact, John’s initial negative TST might represent a false negative due to the incubation period. He will be advised to have a repeat TST 8-10 weeks after his last exposure. He will also be monitored for any symptoms of TB during this period.

This emphasizes the importance of considering the timing of exposure and the potential for a “window period” in TST interpretation. Close contacts often require serial testing.

Case Study 3: The BCG-Vaccinated Individual

Aisha received the BCG vaccine as a child in her home country. Years later, she undergoes a TST for a visa requirement. The test shows a 7mm induration.

A 7mm induration in a BCG-vaccinated individual is often considered potentially due to the vaccine itself. However, guidelines suggest that any induration of 5mm or more in a person with a known TB contact or symptoms should be investigated further. Given Aisha has no symptoms or known exposure, the interpretation might lean towards a vaccine effect, but a confirmatory IGRA blood test could provide more clarity.

This case illustrates the challenge of interpreting TSTs in populations with high BCG vaccination rates. IGRAs offer a valuable alternative in such situations.

Factors Influencing TST Results

Beyond infection status, several external factors can influence the accuracy and interpretation of a TST. Understanding these nuances is critical for accurate diagnosis and appropriate patient management.

The individual’s immune status is paramount. Conditions that suppress the immune system, such as HIV, diabetes, malnutrition, or the use of immunosuppressive medications, can lead to a reduced or absent reaction to the PPD, resulting in a false negative test. Conversely, some individuals might have a hypersensitive immune response that could be misinterpreted.

The technique used for administering and reading the test is also a significant factor. Inconsistent PPD dosage, incorrect injection depth, or imprecise measurement of induration can all lead to erroneous results. Proper training of healthcare personnel is therefore essential.

Furthermore, the presence of other mycobacterial infections, although less common, can sometimes cause a reaction to the PPD, leading to a false positive result. The development of effective treatments for TB and LTBI hinges on the accurate interpretation of these tests, making attention to these influencing factors vital.

The Impact of Immunosuppression

Individuals with compromised immune systems are at a higher risk for TB infection and disease progression. Their immune system’s ability to mount a reaction to the PPD antigen may be significantly diminished.

This anergy can lead to false negative TST results, masking an underlying TB infection. For example, a person with advanced HIV infection might have been exposed to TB but show no reaction on the skin test.

In such cases, alternative diagnostic methods like IGRAs or even symptom-based screening and chest X-rays become more important. Healthcare providers must exercise vigilance when testing immunosuppressed individuals.

The BCG Vaccine and TST Reactivity

The BCG vaccine, while effective against severe TB in children, can interfere with the interpretation of TST results. The vaccine contains live, attenuated Mycobacterium bovis, which shares antigens with Mycobacterium tuberculosis.

This cross-reactivity can cause a positive TST reaction in individuals who have been vaccinated but have never been infected with Mycobacterium tuberculosis. The degree of reactivity can vary, making it difficult to distinguish a true TB infection from a vaccine response based solely on the TST.

For this reason, in populations where BCG vaccination is common, healthcare providers often rely on IGRAs or consider the TST result in conjunction with other clinical information and risk factors.

Other Interfering Factors

Beyond immunosuppression and BCG vaccination, other factors can affect TST results. Recent viral infections, such as measles or influenza, can temporarily suppress the immune system, potentially leading to a false negative TST if administered during the illness.

Certain medications, particularly corticosteroids and other immunosuppressants, can also blunt the immune response. Even incorrect storage or handling of the PPD antigen can reduce its potency and lead to inaccurate results.

It is also important to consider the possibility of infection with non-tuberculous mycobacteria (NTM). While less common than TB infection, exposure to certain NTM species can elicit a TST reaction, although this typically requires a larger induration to be considered significant.

Conclusion: Navigating TB Testing for Better Health

The tuberculin skin test remains a valuable tool in the fight against tuberculosis, but its interpretation requires careful consideration. A positive TST signals potential exposure and necessitates further evaluation to rule out active disease and manage latent infection. A negative TST generally indicates no infection, but awareness of potential false negatives is crucial.

Understanding the nuances of TST administration, reading, and interpretation, along with considering individual risk factors and the impact of BCG vaccination or immunosuppression, is essential for healthcare professionals. The advent of IGRAs provides an important alternative or complementary diagnostic approach.

Ultimately, the goal of TB testing is to identify individuals who need treatment, prevent the spread of the disease, and protect public health. By accurately interpreting TST results and following up appropriately, individuals can make informed decisions about their health and contribute to TB control efforts.